CL2020001638A1 - Nucleic acid molecule for the reduction of papd5 and papd7 mRNA in the treatment of hepatitis b infection. (divisional request 202000945) - Google Patents

Nucleic acid molecule for the reduction of papd5 and papd7 mRNA in the treatment of hepatitis b infection. (divisional request 202000945)

Info

Publication number
CL2020001638A1
CL2020001638A1 CL2020001638A CL2020001638A CL2020001638A1 CL 2020001638 A1 CL2020001638 A1 CL 2020001638A1 CL 2020001638 A CL2020001638 A CL 2020001638A CL 2020001638 A CL2020001638 A CL 2020001638A CL 2020001638 A1 CL2020001638 A1 CL 2020001638A1
Authority
CL
Chile
Prior art keywords
papd5
nucleic acid
treatment
acid molecule
infection
Prior art date
Application number
CL2020001638A
Other languages
Spanish (es)
Inventor
Søren Ottosen
Lykke Pedersen
Henrik Mueller
Susanne Kammler
Anaïs Lopez
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CL2020000945A external-priority patent/CL2020000945A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2020001638A1 publication Critical patent/CL2020001638A1/en

Links

Abstract

La presente invención se refiere a moléculas de ácidos nucleicos que son complementarias a tanto la proteína 5 que contiene el dominio asociado a PAP (PAPD5) como la proteína 7 que contiene el dominio asociado a PAP (PAPD7), que conducen a la inhibición de la expresión de tanto PAPD5 como PAPD7 al utilizar una única molécula de ácidos nucleicos. La invención proporciona además moléculas de ácidos nucleicos específicas de PAPD5 y PAPD7 para la utilización en el tratamiento y/o prevención de una infección por el VHB, en particular una infección crónica por el VHB. Se encuentra comprendida además en la presente invención una composición farmacéutica para la utilización en el tratamiento y/o prevención de una infección por el VHB.The present invention relates to nucleic acid molecules that are complementary to both protein 5 containing the PAP-associated domain (PAPD5) and protein 7 containing the PAP-associated domain (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 using a single nucleic acid molecule. The invention further provides PAPD5 and PAPD7 specific nucleic acid molecules for use in the treatment and / or prevention of an HBV infection, in particular a chronic HBV infection. A pharmaceutical composition for use in the treatment and / or prevention of HBV infection is further encompassed by the present invention.

CL2020001638A 2017-10-16 2020-06-17 Nucleic acid molecule for the reduction of papd5 and papd7 mRNA in the treatment of hepatitis b infection. (divisional request 202000945) CL2020001638A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17196554 2017-10-16
EP17208056 2017-12-18
CL2020000945A CL2020000945A1 (en) 2017-10-16 2020-04-08 Nucleic acid molecule for the reduction of papd5 and papd7 mRNA in the treatment of hepatitis b infection.

Publications (1)

Publication Number Publication Date
CL2020001638A1 true CL2020001638A1 (en) 2020-10-16

Family

ID=73045719

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001638A CL2020001638A1 (en) 2017-10-16 2020-06-17 Nucleic acid molecule for the reduction of papd5 and papd7 mRNA in the treatment of hepatitis b infection. (divisional request 202000945)

Country Status (1)

Country Link
CL (1) CL2020001638A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11191775B2 (en) 2016-06-17 2021-12-07 Hoffmann-La Roche Inc. PAPD5 and PAPD7 inhibitors for treating a hepatitis B infection
US11484546B2 (en) 2017-10-16 2022-11-01 Hoffman-La Roche Inc. Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11191775B2 (en) 2016-06-17 2021-12-07 Hoffmann-La Roche Inc. PAPD5 and PAPD7 inhibitors for treating a hepatitis B infection
US11534452B2 (en) 2016-06-17 2022-12-27 Hoffmann-La Roche Inc. Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection
US11484546B2 (en) 2017-10-16 2022-11-01 Hoffman-La Roche Inc. Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection

Similar Documents

Publication Publication Date Title
MX2020003464A (en) NUCLEIC ACID MOLECULE FOR REDUCTION OF PAPD5 AND PAPD7 mRNA FOR TREATING HEPATITIS B INFECTION.
PE20190443A1 (en) NUCLEIC ACID MOLECULES FOR THE REDUCTION OF PAPD5 OR PAPD7 mRNA TO TREAT HEPATITIS B INFECTION
CL2017002230A1 (en) Combined treatment with a tlr7 agonist and inhibitor of vhb capsid assembly.
AR112271A1 (en) COMPOSITIONS INCLUDING AN INHIBITOR OF RNA POLYMERASE AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
BR112018009009A2 (en) combined therapy of an hbv capsid formation inhibitor and an interferon
BR112015028879A8 (en) heterocyclic derivative compounds, pharmaceutical composition comprising said compounds and uses thereof
BR112019004560A2 (en) combination treatment with tlr7 agonist and a hbv capsid formation inhibitor
UY37581A (en) COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION
BR112016020199A8 (en) human plasma kallikrein inhibitor compound, pharmaceutical composition comprising said compound, kit and its use
CL2020001146A1 (en) New indole-2-carboxamides substituted with pyrazolopiperidine, of high activity, active against the hepatitis b virus (HBV).
BR112015009624A2 (en) bruton tyrosine kinase inhibitors
BR112012024661A2 (en) compound, pharmaceutical composition and method of treating a host infected with hepatitis c virus
BR112020020220A8 (en) use of fubp1 inhibitors to treat hepatitis b virus infection
ECSP088208A (en) NEW MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
BR112013020042A2 (en) hepatitis c virus inhibitors
CL2020001638A1 (en) Nucleic acid molecule for the reduction of papd5 and papd7 mRNA in the treatment of hepatitis b infection. (divisional request 202000945)
AR114551A1 (en) COMPOSITIONS OF hdRNA AGENTS AGAINST HEPATITIS B VIRUS (HBV) AND METHODS FOR THEIR USE
BR112019024549A2 (en) glycopeptide-derived compounds and uses thereof
WO2009138146A3 (en) Novel therapeutic agents against hepatitis
MX2020003473A (en) Novel mek-inhibitor for the treatment of viral and bacterial infections.
CL2021000018A1 (en) Oligonucleotides to modulate the expression of rtel1
BR112022000971A2 (en) Dihydropyrimidine derivatives and their use in the treatment of hbv infection or hbv-induced diseases
BR112015022134A2 (en) compound, pharmaceutical composition, patch, stick, spray dispenser, tube or pen, and method of treating an infection
AR113771A1 (en) NUCLEIC ACID MOLECULE FOR THE REDUCTION OF PAPD5 AND PAPD7 mRNA IN THE TREATMENT OF HEPATITIS B INFECTION
CO2023000116A2 (en) Improved oligonucleotides to modulate fubp1 expression